Crossmark

Certolizumab pegol, ¿un nuevo anti-TNF en el tratamiento de la psoriasis moderada-grave?

Crossref DOI link: https://doi.org/10.1016/j.piel.2017.04.015

Published Print: 2017-12

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Ruiz-Villaverde, Ricardo

Cuenca-Barrales, Carlos

Salvador-Rodriguez, Luis

Ruiz-Carrascosa, José Carlos
License Information

Text and Data Mining valid from 2017-12-01
More Information

This article is maintained by: Elsevier

Article Title: Certolizumab pegol, ¿un nuevo anti-TNF en el tratamiento de la psoriasis moderada-grave?

Journal Title: Piel

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.piel.2017.04.015

Content Type: article

Copyright: © 2017 Elsevier España, S.L.U. All rights reserved.